Stoke Therapeutics (STOK) CEO awarded new stock options and RSUs

Rhea-AI Filing Summary

Stoke Therapeutics reported that Chief Executive Officer Ian F. Smith received new equity awards in the form of options and restricted stock units. He was granted 193,000 employee stock options with an exercise right to buy company shares, which vest monthly over four years starting March 15, 2026, contingent on continued service. He also received 129,000 restricted stock units, each representing a right to one share of common stock, vesting in four annual tranches beginning February 15, 2027, also subject to his continued service.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider SMITH IAN F

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (Right to Buy)	193,000	$0.00	--
Grant/Award	Restricted Stock Units	129,000	$0.00	--

Holdings After Transaction: Employee Stock Option (Right to Buy) — 193,000 shares (Direct); Restricted Stock Units — 129,000 shares (Direct)

Footnotes (1)

1. The option shall vest as to 1/48 of the total award on March 15, 2026, with 1/48 vesting on each monthly anniversary thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock upon settlement. The RSU award shall vest as to 1/4 of the total award annually with the first tranche vesting on February 15, 2027, subject to the reporting person's continued service to the issuer through each vesting date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SMITH IAN F

(Last) (First) (Middle)

C/O STOKE THERAPEUTICS, INC.

45 WIGGINS AVENUE

(Street)

BEDFORD MA 01730

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Stoke Therapeutics, Inc. [ STOK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/17/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$31.09	02/17/2026		A		193,000		(1)	02/16/2036	Common Stock	193,000	$0	193,000	D
Restricted Stock Units	(2)	02/17/2026		A		129,000		(3)	02/15/2030	Common Stock	129,000	$0	129,000	D

Explanation of Responses:

1. The option shall vest as to 1/48 of the total award on March 15, 2026, with 1/48 vesting on each monthly anniversary thereafter, subject to the reporting person's continued service to the issuer through each vesting date.

2. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock upon settlement.

3. The RSU award shall vest as to 1/4 of the total award annually with the first tranche vesting on February 15, 2027, subject to the reporting person's continued service to the issuer through each vesting date.

	/s/ Jonathan Allan, Attorney-in-Fact	02/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Stoke Therapeutics (STOK) report for its CEO?

Stoke Therapeutics reported that CEO Ian F. Smith received equity awards, including stock options and restricted stock units. These awards are part of his compensation and vest over several years, contingent on his continued service with the company.

How many stock options did the Stoke Therapeutics (STOK) CEO receive?

The CEO received 193,000 employee stock options with a right to buy Stoke Therapeutics common stock. These options vest in 48 equal monthly installments starting March 15, 2026, provided he remains in service through each vesting date.

What restricted stock unit grant was reported for Stoke Therapeutics (STOK) CEO?

The CEO was granted 129,000 restricted stock units, each representing one share of common stock upon settlement. These RSUs vest in four equal annual installments, with the first tranche vesting on February 15, 2027, subject to his continued service.

When do the Stoke Therapeutics (STOK) CEO’s stock options start vesting?

The stock options begin vesting on March 15, 2026, with 1/48 of the total award vesting on that date. The remaining portions vest on each monthly anniversary thereafter, assuming the CEO continues his service with Stoke Therapeutics.

When do the restricted stock units for Stoke Therapeutics (STOK) CEO vest?

The restricted stock units vest annually, with 1/4 of the total 129,000-unit award vesting each year. The first annual tranche vests on February 15, 2027, subject to the CEO’s continued service with the company through each vesting date.

Do the Stoke Therapeutics (STOK) CEO’s equity awards require continued service to vest?

Yes. Both the stock options and restricted stock units vest only if the CEO remains in service. The options vest monthly starting March 15, 2026, and the RSUs vest annually beginning February 15, 2027, each conditioned on continued employment.